Equities Analysts Issue Forecasts for BioLineRx Q2 Earnings

BioLineRx Ltd. (NASDAQ:BLRXFree Report) – Research analysts at HC Wainwright upped their Q2 2025 EPS estimates for shares of BioLineRx in a note issued to investors on Wednesday, May 28th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will post earnings of ($0.35) per share for the quarter, up from their prior forecast of ($0.77). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for BioLineRx’s current full-year earnings is ($5.80) per share. HC Wainwright also issued estimates for BioLineRx’s Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.51) EPS and FY2025 earnings at $0.08 EPS.

A number of other analysts also recently issued reports on the stock. Jones Trading raised shares of BioLineRx from a “hold” rating to a “strong-buy” rating in a report on Friday. Wall Street Zen assumed coverage on shares of BioLineRx in a report on Sunday, May 18th. They set a “sell” rating for the company.

Read Our Latest Report on BLRX

BioLineRx Stock Performance

NASDAQ BLRX opened at $5.44 on Friday. The company has a quick ratio of 1.37, a current ratio of 1.52 and a debt-to-equity ratio of 2.11. The company has a market capitalization of $18.11 million, a P/E ratio of -0.62 and a beta of 1.15. BioLineRx has a 12-month low of $2.30 and a 12-month high of $35.60. The firm has a 50-day moving average price of $3.16 and a two-hundred day moving average price of $5.51.

BioLineRx (NASDAQ:BLRXGet Free Report) last posted its quarterly earnings data on Tuesday, May 27th. The biotechnology company reported $1.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.84) by $2.23. The firm had revenue of $11.75 million during the quarter, compared to the consensus estimate of $7.72 million. BioLineRx had a negative net margin of 90.57% and a negative return on equity of 163.37%.

Institutional Trading of BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC purchased a new position in shares of BioLineRx Ltd. (NASDAQ:BLRXFree Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned 50.50% of BioLineRx at the end of the most recent quarter. 1.56% of the stock is currently owned by institutional investors and hedge funds.

BioLineRx Company Profile

(Get Free Report)

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.

Featured Stories

Earnings History and Estimates for BioLineRx (NASDAQ:BLRX)

Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.